A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia
Open accessThe DOI matches its Crossref record.
Abstract
Although there have been several case reports suggesting the beneficial effect of acetylcholinesterase inhibitors in the cognitive deficits seen in schizophrenia, controlled studies have revealed contradictory results. The aim of this study was to investigate if donepezil could improve cognitive functions in schizophrenia. Twelve schizophrenic patients, who were diagnosed according to DSM-IV criteria and who had been on a stable dose of a high-potency typical antipsychotic for a minimum period of 3 months, participated in this 12-wk double-blind, placebo controlled, cross-over study of donepezil adjunctive treatment. Patients were randomly assigned under double-blind conditions to receive 5 mg/d donepezil or placebo for 6 wk, and then were crossed over to the alternate condition for 6 additional weeks. At baseline, 6 and 12 wk, patients were evaluated with the Positive and Negative Syndrome Scale (PANSS), Calgary Depression Scale, the Wechsler Memory Scale Revised (WMS-R), a test for Verbal Fluency, Trail Making Test, Parts A and B, and Wisconsin Card Sorting Test (WCST). Treatment effect was not significant in any of the cognitive measures. There were also no significant changes in the PANSS and depression scores. Nicotinic receptor desensitization may cause non-responsiveness to acetylcholine as previously suggested, but the most likely explanation appears to be that defects in other neurotransmitter systems account for the cognitive deficits seen in schizophrenic patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cognitive deficits and functional outcome in schizophrenia
Bowie, C. R., & Harvey, P. D. (2006) · Neuropsychiatric Disease and Treatment · doi:10.2147/nedt.2006.2.4.531 · Cited by 647
Towards a muscarinic hypothesis of schizophrenia
Raedler, T. J., Bymaster, F. P., Tandon, R., Copolov, D., & Dean, B. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001924 · Cited by 291
Desensitized nicotinic receptors in brain
Wang, H., & Sun, X. (2005) · Brain Research Reviews · doi:10.1016/j.brainresrev.2004.09.003 · Cited by 175
Holtzheimer, P. E., Meeks, T. W., Kelley, M. E., Mufti, M., Young, R., McWhorter, K., Vito, N., Chismar, R., Quinn, S., Dey, S., et al. (2008) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1951 · Cited by 50
Cholinergic Circuits and Signaling in the Pathophysiology of Schizophrenia
Berman, J. A., Talmage, D. A., & Role, L. W. (2007) · International Review of Neurobiology · doi:10.1016/s0074-7742(06)78007-2 · Cited by 47
“Others were in a general population of stable schizophrenic patients (Friedman et al., 2002; Stryjer et al., 2004; Tugal et al., 2004).”
Background
Metadata
- Authors
- Tual, Ö., Yazıcı, K. M., Yacıolu, A. E. A., & Göüş, A.
- Venue
- The International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-06
- Volume
- 7
- Issue
- 2
- Pages
- 117-123
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- OpenAlex
- W2076811752
- Cited by
- 83
- References
- 0
- FWCI
- 7.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. https://app.cochat.ai/papers/10.1017/s1461145703004024
- The paper
- Tual, Ö., Yazıcı, K. M., Yacıolu, A. E. A., & Göüş, A. (2004). A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. The International Journal of Neuropsychopharmacology. https://doi.org/10.1017/s1461145703004024
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.